STAAR Surgical (Nasdaq: STAA) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 30 (Q1), STAAR Surgical missed estimates on revenue and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved and GAAP earnings per share was unchanged.

Gross margin and operating margin grew, while net margins contracted.

Revenue details
STAAR Surgical notched revenue of $15.5 million. The five analysts polled by S&P Capital IQ expected net sales of $16.9 million on the same basis. GAAP-reported sales were 4.4% higher than the prior-year quarter's $14.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.04. The three earnings estimates compiled by S&P Capital IQ predicted $0.03 per share. GAAP EPS of $0.01 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 70.3%, 550 basis points better than the prior-year quarter. Operating margin was 1.8%, 40 basis points better than the prior-year quarter. Net margin was 1.5%, 50 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $18.5 million. On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $72.8 million. The average EPS estimate is $0.13.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 93 members rating the stock outperform and 13 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give STAAR Surgical a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $12.60.

The health-care investing landscape is littered with also-rans and a few major winners. Is STAAR Surgical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.